SQI snags $4.2M to dial up its marketing push

SQI Diagnostics has raised $4.2 million through a public offering, selling off shares and warrants to bankroll its commercialization plans. The company makes most of its revenue off of companion diagnostics partnerships with drugmakers, but SQI is working toward winning FDA clearance for an in vitro test for celiac disease. More

Suggested Articles

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.

Adaptive Biotechnologies is planning a $200 million IPO to help power its sequencing tests aimed at the body’s immune system and related therapies.

Abbott’s new diabetes test provides A1c results in three minutes, allowing clinicians to develop care plans within a single office visit.